BOSTON, MA, February 2, 2021
HD LifeSciences, LLC announced that industry veteran Patrick O’Donnell has joined the company as the new President & Chief Executive Office. For over 25 years, Mr. O’Donnell has established a successful track record in the medical device, orthobiologics, and biomaterials industries with technologies in the orthopedic, spine, neurosurgery, and sports medicine markets.
In his new role, Mr. O’Donnell will be responsible for overseeing all aspects of the business’s operations with significant focus on leading the company’s Commercial, Clinical, and Product Development strategy aimed at leveraging the company’s innovative, flagship product portfolio of Hive™ 3D printed interbody fusion cages with proprietary Soft Titanium™ technology.
Mr. O’Donnell has held CEO positions at early-stage, clinical stage, and pre-commercial stage medical device and combination product companies, executive sales and marketing roles, and started his career in commercial positions of escalating responsibility at DePuy Spine. “Patrick’s extensive strategic development and execution experiences combined with his organization team-building and commercial leadership will bring tremendous value to HD LifeSciences during this exciting time in the company’s growth.” added Mr. Tim Helfet, a Managing Director at the company.
About HD LifeSciences
HD LifeSciences is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company’s proprietary, biomimetic Soft Titanium™ technology clearly distinguishes their products in the $1.5B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. HD Lifesciences is located in Woburn, Massachusetts U.S.A
Contact: Patrick O’Donnell at firstname.lastname@example.org
SOURCE: LifeScience, 1st February 2021